1. Ministry of Health and Welfare; Korea Central Cancer Registry; National Cancer Center. Annual report of cancer statistics in Korea in 2016 [Internet]. Goyang (KR): National Cancer Center, 2016. [cited 2020 Feb 24]. Available from:
https://ncc.re.kr/main.ncc?uri=english/sub04_Statistics.
2. Kim YC, Won YJ. The development of the Korean lung cancer registry (KALC-R). Tuberc Respir Dis (Seoul) 2019;82:91–93.
3. Park CK, Kim SJ. Trends and updated statistics of lung cancer in Korea. Tuberc Respir Dis (Seoul) 2019;82:175–177.
4. Korean Statistical Information Service. Causes of death statistics in 2018 [Internet]. Daejeon (KR): KOSIS, 2018. [cited 2020 Feb 24]. Available from:
http://kosis.kr.
5. Yeo CD, Lee MK, Lee SH, et al. Indicators and qualitative assessment of lung cancer management by Health Insurance Review and Assessment Service (HIRA) of Korea in 2015. Tuberc Respir Dis (Seoul) 2018;81:19–28.
6. Gucalp R, Dutcher JP. Oncologic Emergencies. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 20th ed. Vol. 1. New York (NY): McGraw Hill Educations, 2018;511–512.
7. Horn L, Lovely CM. Neoplasms of the lung. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 20th ed. Vol. 1. New York (NY): McGraw Hill Education, 2018;537–555.
8. Jameson JL, Longo DL. Paraneoplastic syndromes: endocrinologic/hematologic. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 20th ed. Vol. 1. New York (NY): McGraw Hill Education, 2018;662–668.
11. Goldberg SB, Contessa JN, Omay SB, Chiang V. Lung cancer brain metastases. Cancer J 2015;21:398–403.
13. Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw 2019;17:1464–1472.
15. Sampsonas F, Kakoullis L, Lykouras D, Karkoulias K, Spiropoulos K. EBUS: faster, cheaper and most effective in lung cancer staging. Int J Clin Pract 2018;72.
16. Kim SY, Lee JW, Park YS, et al. Incidence of fever following endobronchial ultrasound-guided transbronchial needle aspiration. Tuberc Respir Dis (Seoul) 2017;80:45–51.
17. Dong X, Qiu X, Liu Q, Jia J. Endobronchial ultrasound-guided transbronchial needle aspiration in the mediastinal staging of non-small cell lung cancer: a meta-analysis. Ann Thorac Surg 2013;96:1502–1507.
18. Tournoy KG, Rintoul RC, van Meerbeeck JP, et al. EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer 2009;63:45–49.
21. Mehta AC, Hood KL, Schwarz Y, Solomon SB. The evolutional history of electromagnetic navigation bronchoscopy: state of the art. Chest 2018;154:935–947.
22. Yarmus LB, Arias S, Feller-Kopman D, et al. Electromagnetic navigation transthoracic needle aspiration for the diagnosis of pulmonary nodules: a safety and feasibility pilot study. J Thorac Dis 2016;8:186–194.
23. Gex G, Pralong JA, Combescure C, Seijo L, Rochat T, Soccal PM. Diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta-analysis. Respiration 2014;87:165–176.
24. DiBardino DM, Yarmus LB, Semaan RW. Transthoracic needle biopsy of the lung. J Thorac Dis 2015;7:S304–S316.
30. Kim HJ, Lee KY, Kim YC, et al. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012;75:321–325.
33. Garinet S, Laurent-Puig P, Blons H, Oudart JB. Current and future molecular testing in NSCLC, what can we expect from new sequencing technologies? J Clin Med 2018;7:144.
35. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659–3662.
36. Fang R, Zheng C, Sun Y, et al. Integrative genomic analysis reveals a high frequency of LKB1 genetic alteration in Chinese lung adenocarcinomas. J Thorac Oncol 2014;9:254–258.
37. South Korea Ministry of Health and Welfare; Ministry of Health and Welfare. Notice 2017-19. Partial revision to details on criteria and method of application for medical care benefits [Internet]. Sejong (KR): MOHW, 2017. [cited 2020 Feb 25]. Available from:
http://www.mohw.go.kr/react/jb/sjb0406vw.jsp.
41. Bang MS, Kang K, Lee JJ, et al. Transcriptome analysis of non-small cell lung cancer and genetically matched adjacent normal tissues identifies novel prognostic marker genes. Genes Genom 2017;39:277–284.
42. Gesthalter YB, Vick J, Steiling K, Spira A. Translating the transcriptome into tools for the early detection and prevention of lung cancer. Thorax 2015;70:476–481.
45. Thorne-Nuzzo T, Williams C, Catallini A, et al. A sensitive ALK immunohistochemistry companion diagnostic test identifies patients eligible for treatment with Crizotinib. J Thorac Oncol 2017;12:804–813.
46. Jung CY, Antonia SJ. Tumor immunology and immune checkpoint inhibitors in non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2018;81:29–41.
48. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 2018;142:89–108.
50. Kang BJ, Ra SW, Lee K, et al. Circulating tumor cell number is associated with primary tumor volume in patients with lung adenocarcinoma. Tuberc Respir Dis (Seoul) 2020;83:61–70.